Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Cinrebafusp alfa |
| Trade Name | |
| Synonyms | PRS-343|PRS 343|PRS343 |
| Drug Descriptions |
Cinrebafusp alfa is a bispecific antibody that targets both TNFRSF9 (CD137; 4-1BB) and ERBB2 (HER2), potentially resulting in enhanced anti-tumor immune response against Erbb2 (Her2)-positive tumor cells (PMID: 31138587, PMID: 39235868). |
| DrugClasses | HER2 (ERBB2) Antibody 79 TNFRSF9 Antibody 36 |
| CAS Registry Number | 2218515-90-1 |
| NCIT ID | C142890 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atezolizumab + Cinrebafusp alfa | Atezolizumab Cinrebafusp alfa | 0 | 1 |
| Cinrebafusp alfa | Cinrebafusp alfa | 0 | 1 |
| Cinrebafusp alfa + Paclitaxel + Ramucirumab | Cinrebafusp alfa Paclitaxel Ramucirumab | 0 | 1 |
| Cinrebafusp alfa + Tucatinib | Cinrebafusp alfa Tucatinib | 0 | 1 |